$IMMX News

Immix Biopharma (IMMX) Stock Sees Modest Fair Value Lift After Split Analyst Revisions

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript

Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial

Needham Maintains Buy on Immix Biopharma, Raises Price Target to $30

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis

Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $26

Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19

HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Needham Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $21

All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy

Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet

Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions

B of A Securities Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $27

Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock